Literature DB >> 11221797

Impact of the new WHO classification and diagnostic criteria.

P H Bennett1.   

Abstract

The World Health Organisation (WHO) [1] consultation group and the American Diabetes Association (ADA) [2] have recently published revised criteria for the classification and diagnosis of diabetes. If widely implemented, these recommendations, together with earlier and improved treatment, could have a profound impact on the morbidity and mortality associated with the disease. The changes in classification stem from an increased knowledge of the aetiology and pathogenesis of diabetes, which signals the move away from a classification system based on pharmacological dependency towards one that is based on the underlying causes of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 11221797     DOI: 10.1046/j.1463-1326.1999.0010s2001.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  7 in total

1.  Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia.

Authors:  Jialin Gao; Qianyin Xiong; Jun Miao; Yao Zhang; Libing Xia; Meiqin Lu; Binhua Zhang; Yueping Chen; Ansu Zhang; Cui Yu; Li-Zhuo Wang
Journal:  Biomed Rep       Date:  2015-02-19

2.  The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.

Authors:  Abdolkarim Mahrooz; Hassan Parsanasab; Mohammad Bagher Hashemi-Soteh; Zahra Kashi; Adele Bahar; Ahad Alizadeh; Maliheh Mozayeni
Journal:  Clin Exp Med       Date:  2014-04-17       Impact factor: 3.984

3.  Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy.

Authors:  Hao Zhang; Xu Cai; Bin Yi; Jing Huang; Jianwen Wang; Jian Sun
Journal:  Mol Med Rep       Date:  2014-03-24       Impact factor: 2.952

4.  STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus.

Authors:  Qingchu Li; Cuilin Li; Haoyun Li; Liu Zeng; Zhiqiang Kang; Yu Mao; Xinyue Tang; Panpan Zheng; Li He; Fang Luo; Zhi Li
Journal:  Int J Endocrinol       Date:  2017-07-09       Impact factor: 3.257

5.  Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes.

Authors:  Jingyi Hu; Zhiwen Liu; Yue Tong; Zubing Mei; Aimin Xu; Pengcheng Zhou; Xiaoyan Chen; Weili Tang; Zhiguang Zhou; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-22       Impact factor: 5.555

6.  The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.

Authors:  Zahra Kashi; Abdolkarim Mahrooz; Anvarsadat Kianmehr; Ahad Alizadeh
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

7.  Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.

Authors:  Fazlollah Shokri; Hamid Ghaedi; Soudeh Ghafouri Fard; Abolfazl Movafagh; Saeid Abediankenari; Abdolkarim Mahrooz; Zahra Kashi; Mir Davood Omrani
Journal:  Int J Mol Cell Med       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.